Track whether the sale actually executes — large insider selling by a former officer over two months may signal reduced conviction or planned diversification. Monitor for any material non-public catalysts (upcoming data readouts, guidance updates). Consider the selling into the current bullish analyst consensus (65% buy) as a potential contrarian signal.
Price Chart
Executive Summary
Former officer Sandip Kapadia filed a Form 144 notice to sell 50,000 shares of Harmony Biosciences, valued at approximately $1.8M. This follows a string of recent sales by Kapadia in May and June 2026 totaling approximately $4.5M, raising concerns about insider conviction ahead of potential catalysts.
Key Facts
- Former officer Sandip Kapadia filed Form 144 to sell 50,000 shares valued at ~$1.8M.
- Kapadia executed prior sales: 45,594 shares on 06/26 (~$1.6M), 4,406 on 06/24 (~$0.15M), 27,960 on 06/09 (~$0.94M), 2,101 on 06/05 (~$0.07M), 7,064 on 06/04 (~$0.23M), and 45,481 on 05/08 (~$1.43M).
- Total recent sales by this insider exceed $4.5M in aggregate.
- The proposed sale is for 50,000 shares (no remaining holdings disclosed in filing).
- HRMY market cap is $2.1B; the proposed block is ~0.09% of market cap.
Financial Impact
Proposed sale of 50,000 shares valued at ~$1.8M, plus ~$4.5M in prior sales since May 2026 — total insider cash-out ~$6.3M.
Risk Factors
- Form 144 is intent to sell — execution is not guaranteed.
- Insider may have tax or estate-planning motives unrelated to company outlook.
- Historical reports on HRMY show 100% win rate at T+20, suggesting prior analysis has been accurate but stock could continue to rise despite insider selling.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-006634 |
| Document: 0001950047-26-006634-index.html | 0001950047-26-006634 |
| Document: 0001950047-26-006634.txt | 0001950047-26-006634 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 4, 2026 8w ago | 8-K | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Aug 4, 2026 8w ago | Press Release | $38.78 $39.52 | ▲ +1.91% | ▲ +2.01% | $40.53 (+4.53%) |
Jul 16, 2026 11w ago | 8-K | $33.53 $35.80 | ▲ +6.77% | ▲ +8.44% | $40.53 (+20.89%) |
Jun 30, 2026 13w ago | 144 | $36.00 $38.26 | ▼ −6.28% | ▼ −6.02% | $40.53 (−12.60%) |
Jun 24, 2026 14w ago | 144 | $34.13 $36.00 | ▼ −5.48% | ▼ −3.92% | $40.53 (−18.77%) |
Jun 9, 2026 16w ago | 144 | $35.48 $33.83 | ▼ −4.65% | ▼ −8.08% | $40.53 (+14.25%) |
Jun 5, 2026 16w ago | 144 | $32.39 $34.18 | ▲ +5.53% | ▲ +3.41% | $40.53 (+25.15%) |
May 19, 2026 19w ago | 3 | $30.44 $30.76 | ▲ +1.05% | ▼ −1.25% | $40.53 (+33.16%) |
May 7, 2026 21w ago | 8-K | $31.42 $30.83 | ▼ −1.88% | ▼ −3.38% | $40.53 (+29.01%) |
Apr 14, 2026 24w ago | 8-K | $29.29 $32.14 | ▲ +9.73% | ▲ +8.34% | $40.53 (+38.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access